An economic model of long-term use of celecoxib in patients with osteoarthritis

BMC Gastroenterology

Philip Jacobs²  Dale Rublee³  Michael Loyd¹ 

[1]Michael Loyd & Associates Ltd, Winnipeg, Manitoba, Canada

[2]University of Alberta, Edmonton, Alberta, Canada

[3]Global Outcomes Research, Pfizer Inc, New York, USA

Others  :  1211646
DOI  :  10.1186/1471-230X-7-25

 received in 2007-01-08, accepted in 2007-07-04,  发布年份 2007

【 摘 要 】

Background

Previous evaluations of the cost-effectiveness of the cyclooxygenase-2 selective inhibitor celecoxib (Celebrex, Pfizer Inc, USA) have produced conflicting results. The recent controversy over the cardiovascular (CV) risks of rofecoxib and other coxibs has renewed interest in the economic profile of celecoxib, the only coxib now available in the United States. The objective of our study was to evaluate the long-term cost-effectiveness of celecoxib compared with nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) in a population of 60-year-old osteoarthritis (OA) patients with average risks of upper gastrointestinal (UGI) complications who require chronic daily NSAID therapy.

Methods

We used decision analysis based on data from the literature to evaluate cost-effectiveness from a modified societal perspective over patients' lifetimes, with outcomes expressed as incremental costs per quality-adjusted life-year (QALY) gained. Sensitivity tests were performed to evaluate the impacts of advancing age, CV thromboembolic event risk, different analytic horizons and alternate treatment strategies after UGI adverse events.

Results

Our main findings were: 1) the base model incremental cost-effectiveness ratio (ICER) for celecoxib versus nsNSAIDs was $31,097 per QALY; 2) the ICER per QALY was $19,309 for a model in which UGI ulcer and ulcer complication event risks increased with advancing age; 3) the ICER per QALY was $17,120 in sensitivity analyses combining serious CV thromboembolic event (myocardial infarction, stroke, CV death) risks with base model assumptions.

Conclusion

Our model suggests that chronic celecoxib is cost-effective versus nsNSAIDs in a population of 60-year-old OA patients with average risks of UGI events.

【 授权许可】

   
2007 Loyd et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 4.

【 参考文献 】

• [1]Dubois RW, Melmed GY, Henning JM, Bernal M: Risk of upper gastrointestinal injury and events in patients treated with cyclooxygenase (COX)-1/COX-2 nonsteroidal antiinflammatory drugs (NSAIDs), COX-2 selective NSAIDs, and gastroprotective cotherapy. An appraisal of the literature. J Clin Rheumatol 2004, 10:178-189.
• [2]Smalley WE, Griffin MR, Fought RL, Ray WA: Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996, 11:461-469.
• [3]Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888-1899.
• [4]Ashton T: Cost-effectiveness of alternative medications in the treatment of duodenal ulcer. Scand J Gastroenterol 1991, 26:82-88.
• [5]Griffin MR: Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998, 104:23S-29S.
• [6]Henke CJ, Levin TR, Henning JM, Potter LP: Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000, 95:788-792.
• [7]Logan R, Delaney B: ABC of the upper gastrointestinal tract: implications of dyspepsia for the NHS. BMJ 2001, 323:675-677.
• [8]Severens JL, Laheij RJ, Jansen JB, Van der Lisdonk EH, Verbeek AL: Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther 1998, 12:919-923.
• [9]Sonnenberg A, Everhart JE: Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997, 92:614-620.
• [10]Tibblin G: Introduction to the epidemiology of dyspepsia. Scand J Gastroenterol Suppl 1985, 109:29-33.
• [11]Bae SC, Corzillius M, Kuntz KM, Liang MH: Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:46-53.
• [12]Spiegel BM, Targownik L, Dulai GS, Gralnek IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003, 138:795-806.
• [13]Yun HR, Bae SC: Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol Int 2005, 25:9-14.
• [14]Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002, 325:619-626.
• [15]Simon LS, White W, MacDonald T, Pan S, Rosenstein R, Gaffney M: Cardiovascular safety of celecoxib: a meta-analysis of 41 clinical studies in 44,300 patients [abstract]. Presented at the American College of Rheumatology Annual Meeting, November 12-17, 2005; San Diego, CA; 2005.
• [16]Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NA, Eisen GM, Stenson WF, Triadafilopoulos G, Investigators SUCCESSI: Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study [published correction appears in: Am J Med. 2006;119:801]. Am J Med 2006, 119:255-266.
• [17]White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92:411-418.
• [18]Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099.
• [19]Hsu PI, Lai KH, Lo GH, Tseng HH, Lo CC, Chen HC, Tsai WL, Jou HS, Peng NJ, Chien CH, Chen JL, Hsu PN: Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002, 51:15-20.
• [20]Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. November 1997 [https://www.ccohta.ca/publications/pdf/peg_e.pdf] webcite 1997.
• [21]Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
• [22]Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528, 2 pages following.
• [23]Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000, 95:1681-1690.
• [24]Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002, 325:624.
• [25]Fries JF, Williams CA, Bloch DA, Michel BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991, 91:213-222.
• [26]Fries JF: The epidemiology of NSAID gastropathy. The ARAMIS experience. J Clin Rheumatol 1998, 4:S11-S16.
• [27]MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG: Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997, 315:1333-1337.
• [28]Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999, 56:18-24.
• [29]Wolfe F, Hawley DJ: The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000, 27:1668-1673.
• [30]Serrano P, Lanas A, Arroyo MT, Ferreira IJ: Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002, 16:1945-1953.
• [31]Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
• [32]Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS: Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000, 27:1876-1883.
• [33]El Serag HB, Talley NJ: Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004, 19:643-654.
• [34]Goldstein JL, Eisen GM, Burke TA, Pena BM, Lefkowith J, Geis GS: Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002, 16:819-827.
• [35]McKenna F, Arguelles L, Burke T, Lefkowith J, Geis GS: Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002, 20:35-43.
• [36]Kaplan RM, Anderson JP, Wu AW, Mathews WC, Kozin F, Orenstein D: The Quality of Well-being Scale. Applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989, 27:S27-S43.
• [37]Maetzel A, Krahn M, Naglie G: The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003, 49:283-292.
• [38]Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, Levin TR, Allison JE: Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol 2001, 96:338-347.
• [39]Canadian Institute for Health Information. Canadian Community Health Survey (CCHS): Cycle 1.1: extending the wealth of health data in Canada. 2003 [http://www.statcan.ca/english/concepts/health/cchsinfo.htm] webcite 2003.
• [40]Health Services Cost Review Commission. Maryland Inpatient Public Use File July 2003-June 2004. 2004.
• [41]Ebell MH, Warbasse L, Brenner C: Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997, 44:545-555.
• [42]Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML: Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut 1991, 32:730-734.
• [43]Rorbaek-Madsen M, Fischer L, Thomsen H, Wara P: Late outcome of bleeding gastric ulcer. Five to eight years' follow-up. Scand J Gastroenterol 1994, 29:983-987.
• [44]Singh G, Rosen RD: NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998, 51:8-16.
• [45]Zeidler H: Epidemiology and economics of NSAID-induced gastropathy. Scand J Rheumatol Suppl 1992, 92:3-8.
• [46]North of England Dyspepsia Guideline Development Group. Dyspepsia: managing dyspepsia in adults in primary care. Newcastle upon Tyne (UK): Center for Health Services Research, University of Newcastle. August 2004 [http://www.guideline.gov/summary/pdf.aspx?doc_id=5634&stat=1&string=] webcite 2004.
• [47]Eisen GM, Dominitz JA, Faigel DO, Goldstein JA, Kalloo AN, Petersen BT, Raddawi HM, Ryan ME, Vargo JJ III, Young HS, Fanelli RD, Hyman NH, Wheeler-Harbaugh J: The role of endoscopy in dyspepsia. Gastrointest Endosc 2001, 54:815-817.
• [48]Laheij RJ, Severens JL, Jansen JB, van de Lisdonk EH, Verbeek AL: Management in general practice of patients with persistent dyspepsia. A decision analysis. J Clin Gastroenterol 1997, 25:563-567.
• [49]Laheij RJ, van Rossum LG, Heinen N, Jansen JB: Long-term follow-up of empirical treatment or prompt endoscopy for patients with persistent dyspeptic symptoms? Eur J Gastroenterol Hepatol 2004, 16:785-789.
• [50]Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK: Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005, 118:1271-1278.
• [51]Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134:361-369.
• [52]Lindell GH, Celebioglu F, Graffner HO: Non-ulcer dyspepsia in the long-term perspective. Eur J Gastroenterol Hepatol 1995, 7:829-833.
• [53]Meineche-Schmidt V, Talley NJ, Pap A, Kordecki H, Schmid V, Ohlsson L, Wahlqvist P, Wiklund I, Bolling-Sternevald E: Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol 1999, 34:566-574.
• [54]Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ: Long term acid suppressing treatment in general practice. BMJ 1994, 308:827-830.
• [55]Heikkinen M, Farkkila M: What is the long-term outcome of the different subgroups of functional dyspepsia? Aliment Pharmacol Ther 2003, 18:223-229.
• [56]Janssen HA, Muris JW, Knottnerus JA: The clinical course and prognostic determinants of non-ulcer dyspepsia: a literature review. Scand J Gastroenterol 1999, 34:546-550.
• [57]Jensen DM: Economic assessment of peptic ulcer disease treatments. Scand J Gastroenterol Suppl 1988, 146:214-224.
• [58]McCarthy DM: Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 1989, 96:662-674.
• [59]Petersen H, Kristensen P, Johannessen T, Kleveland PM, Dybdahl JH, Myrvold H: The natural course of peptic ulcer disease and its predictors. Scand J Gastroenterol 1995, 30:17-24.
• [60]Everhart JE, Byrd-Holt D, Sonnenberg A: Incidence and risk factors for self-reported peptic ulcer disease in the United States. Am J Epidemiol 1998, 147:529-536.
• [61]Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. July 1998 [http://www.cbo.gov/showdoc.cfm?index=655&sequence=0.] webcite 1998.
• [62]Anis AH, Guh DP, Woolcott J: Lowering generic drug prices: less regulation equals more competition. Med Care 2003, 41:135-141.
• [63]Frank RG, Seiguer E: Generic drug competition in the US. [http:/ / www.touchbriefings.com/ cdps/ cditem.cfm?NID=15&CID=5&CFID=450567 7&CFTOKEN=96259395] webcite 2003.
• [64]Grabowski H: Patents, innovation and access to new pharmaceuticals. Duke University. [http://levine.sscnet.ucla.edu/archive/grabow-patents_innov.pdf] webcite 2002.
• [65]Newhouse JP: US and UK health economics: two disciplines separated by a common language? Health Econ 1998, 7 Suppl 1:S79-S92.
• [66]Bombardier C: An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002, 89:3D-9D.
• [67]Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B: The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004, 50:2433-2440.
• [68]Hernandez-Diaz S, Rodriguez LA: Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002, 55:157-163.
• [69]Laine L: Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003, 25:S32-S40.
• [70]Tannenbaum H, Peloso PM, Russell AS, Marlow B: An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000, 7 Suppl A:4A-16A.
• [71]Longstreth GF: Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995, 90:206-210.
• [72]Moore RA: Helicobacter pylori and peptic ulcer, a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be cost effective. [http://www.jr2.ox.ac.uk/bandolier/bandopubs/hpyl/hpall.html] webcite 1994.
• [73]Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
• [74]Claxton K: The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999, 18:341-364.
• [75]Hawkey CJ, Langman MJ: Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003, 52:600-608.
• [76]Hunt RH, Barkun AN, Baron D, Bombardier C, Bursey FR, Marshall JR, Morgan DG, Pare P, Thomson AB, Whittaker JS: Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002, 16:231-240.
• [77]Laine L: Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Rev Gastroenterol Disord 2004, 4 Suppl 4:S33-S41.
• [78]Drummond MF, O'Brien B, Stoddart GL, Torrance GW, editors: Methods for the Economic Evaluation of Health Care Programmes. New York, Oxford University Press; 1997.
• [79]Gold MR, Siegel JE, Russell LB, Weinstein MC, editors: Cost-effectiveness in Health and Medicine. New York, Oxford University Press; 1996.
• [80]Maetzel A, Krahn M, Naglie G: The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment Technology Report No. 23. 2001.
• [81]Chancellor JV, Hunsche E, de Cruz E, Sarasin FP: Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001, 19 Suppl 1:59-75.
• [82]Haglund U, Svarvar P: The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000, 39 Suppl 2:51-56.
• [83]Svarvar P, Aly A: Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (Oxford) 2000, 39 Suppl 2:43-50.
• [84]You JH, Lee KK, Chan TY, Lau WH, Chan FK: Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment Pharmacol Ther 2002, 16:2089-2096.
• [85]Zabinski RA, Burke TA, Johnson J, Lavoie F, Fitzsimon C, Tretiak R, Chancellor JV: An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001, 19 Suppl 1:49-58.
• [86]El Serag HB, Graham DY, Richardson P, Inadomi JM: Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med 2002, 162:2105-2110.
• [87]Schaefer M, DeLattre M, Gao X, Stephens J, Botteman M, Morreale A: Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr Med Res Opin 2005, 21:47-60.
• [88]Geis GS: Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial. BMJ 2002, 325:161.
• [89]Gottlieb S: Researchers deny any attempt to mislead the public over JAMA article on arthritis drug. BMJ 2001, 323:301.
• [90]Hrachovec JB, Mora M: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001, 286:2398-2400.
• [91]Juni P, Rutjes AW, Dieppe PA: Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002, 324:1287-1288.
• [92]Juni P, Sterchi R, Dieppe P: Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity. BMJ 2003, 326:334.
• [93]Scheiman JM: Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr Pharm Des 2003, 9:2197-2206.
• [94]Stover RR: Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis. BMJ 2002, 325:161.
• [95]Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS: The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005, 21:715-722.
• [96]Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364:665-674.
• [97]Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P: Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. Aliment Pharmacol Ther 2004, 20:51-63.
• [98]Garcia Rodriguez LA, Hernandez-Diaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004, 159:23-31.
• [99]Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997, 8:18-24.
• [100]Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, Varas-Lorenzo C: Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy 1999, 19:854-859.
• [101]Singh G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.
• [102]Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
• [103]Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996, 312:1563-1566.
• [104]Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:1075-1078.
• [105]Drummond M, McGuire A, editors: Economic Evaluation in Health Care. Merging Theory With Practice. London, Oxford University Press; 2001.
• [106]Andersohn F, Suissa S, Garbe E: Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006, 113:1950-1957.
• [107]Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481.
• [108]Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366.
• [109]Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT: Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan : an observational study. Drug Saf 2006, 29:261-272.
• [110]Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005, 165:978-984.
• [111]Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-164.
• [112]Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005, 142:481-489.
• [113]Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003, 163:481-486.
• [114]Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071-1073.
• [115]Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD: Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005, 165:181-186.
• [116]Singh G, Graham D, Wang H, Mithal A, Triadafilopoulos G: Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs [abstract]. Presented at the European League Against Rheumatism Annual Meeting, June 21-26, 2006, The Netherlands; 2006.
• [117]Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068-2073.
• [118]Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S: Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006, 54:1378-1389.
• [119]Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM: Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 2006.
• [120]McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
• [121]Norgard B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis S, Sorensen HT: COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004, 19:817-825.
• [122]Bergman L, van der Meulen JH, Limburg M, Habbema JD: Costs of medical care after first-ever stroke in The Netherlands. Stroke 1995, 26:1830-1836.
• [123]Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ, Donnan GA: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001, 32:2409-2416.
• [124]Diringer MN, Edwards DF, Mattson DT, Akins PT, Sheedy CW, Hsu CY, Dromerick AW: Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke 1999, 30:724-728.
• [125]Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, Mark DB: Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 2001, 39:824-835.
• [126]Ghatnekar O, Persson U, Glader EL, Terent A: Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004, 20:375-380.
• [127]Salkeld G, Phongsavan P, Oldenburg B, Johannesson M, Convery P, Graham-Clarke P, Walker S, Shaw J: The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 1997, 41:105-119.
• [128]Samsa GP, Bian J, Lipscomb J, Matchar DB: Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999, 30:338-349.
• [129]Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK: Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001, 135:870-883.
• [130]Bronnum-Hansen H, Davidsen M, Thorvaldsen P: Long-term survival and causes of death after stroke. Stroke 2001, 32:2131-2136.
• [131]Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C: Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994, 25:333-337.
• [132]Gage BF, Cardinalli AB, Owens DK: Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998, 29:1083-1091.
• [133]Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EG: Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000, 31:2080-2086.
• [134]Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C: Ten-year survival after first-ever stroke in the perth community stroke study. Stroke 2003, 34:1842-1846.
• [135]Hodgson C: Prevalence and disabilities of community-living seniors who report the effects of stroke. Can Med Assoc J 1998, 159:S9-S14.
• [136]Kiyohara Y, Kubo M, Kato I, Tanizaki Y, Tanaka K, Okubo K, Nakamura H, Iida M: Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke 2003, 34:2343-2347.
• [137]Launbjerg J, Fruergaard P, Madsen JK, Mortensen LS, Hansen JF: Ten year mortality in patients with suspected acute myocardial infarction. BMJ 1994, 308:1196-1199.
• [138]Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999, 30:736-743.
• [139]Simoons ML, Vos J, Martens LL: Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991, 12:694-699.
• [140]Tengs TO, Lin TH: A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003, 21:191-200.
• [141]Heart Disease and Stroke Statistics - 2005 update. American Heart Association [http:/ / www.americanheart.org/ downloadable/ heart/ 1105390918119HDSStats2005Update.pdf] webcite 2005.
• [142]McGovern PG, Jacobs DR Jr., Shahar E, Arnett DK, Folsom AR, Blackburn H, Luepker RV: Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001, 104:19-24.
• [143]Williams GR, Jiang JG, Matchar DB, Samsa GP: Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999, 30:2523-2528.
• [144]Almela P, Benages A, Peiro S, Minguez M, Pena A, Pascual I, Mora F: Outpatient management of upper digestive hemorrhage not associated with portal hypertension: a large prospective cohort. Am J Gastroenterol 2001, 96:2341-2348.
• [145]Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G: Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study. Gastrointest Endosc 2004, 60:1-8.
• [146]Cebollero-Santamaria F, Smith J, Gioe S, Van Frank T, Mc CR, Airhart J, Perrillo R: Selective outpatient management of upper gastrointestinal bleeding in the elderly. Am J Gastroenterol 1999, 94:1242-1247.
• [147]Longstreth GF, Feitelberg SP: Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage. Lancet 1995, 345:108-111.
• [148]Peura DA, Lanza FL, Gostout CJ, Foutch PG: The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 1997, 92:924-928.
• [149]Podila PV, Ben Menachem T, Batra SK, Oruganti N, Posa P, Fogel R: Managing patients with acute, nonvariceal gastrointestinal hemorrhage: development and effectiveness of a clinical care pathway. Am J Gastroenterol 2001, 96:208-219.
• [150]Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, Rahme E, Toubouti Y, Martel M, Chiba N, Fallone CA: The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004, 99:1238-1246.
• [151]Barkun AN, Cockeram AW, Plourde V, Fedorak RN: Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999, 13:1565-1584.
• [152]Branicki FJ, Coleman SY, Fok PJ, Pritchett CJ, Fan ST, Lai EC, Mok FP, Cheung WL, Lau PW, Tuen HH, .: Bleeding peptic ulcer: a prospective evaluation of risk factors for rebleeding and mortality. World J Surg 1990, 14:262-269.
• [153]Garripoli A, Mondardini A, Turco D, Martinoglio P, Secreto P, Ferrari A: Hospitalization for peptic ulcer bleeding: evaluation of a risk scoring system in clinical practice. Dig Liver Dis 2000, 32:577-582.
• [154]Katschinski B, Logan R, Davies J, Faulkner G, Pearson J, Langman M: Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci 1994, 39:706-712.
• [155]Klebl FH, Bregenzer N, Schofer L, Tamme W, Langgartner J, Scholmerich J, Messmann H: Comparison of inpatient and outpatient upper gastrointestinal haemorrhage. Int J Colorectal Dis 2005, 20:368-375.
• [156]Lazzaroni M, Bianchi PG: Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 2004, 20 Suppl 2:48-58.
• [157]Masson J, Bramley PN, Herd K, McKnight GM, Park K, Brunt PW, McKinlay AW, Sinclair TS, Mowat NA: Upper gastrointestinal bleeding in an open-access dedicated unit. J R Coll Physicians Lond 1996, 30:436-442.
• [158]Phang TS, Vornik V, Stubbs R: Risk assessment in upper gastrointestinal haemorrhage: implications for resource utilisation. N Z Med J 2000, 113:331-333.
• [159]Abt Associates Clinical Trials. SUCCESS-1 costing review for the United States. 2004.
• [160]Spiegel BM, Vakil NB, Ofman JJ: Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002, 122:1270-1285.